C

Comprehensive Cancer Centers of Nevada | Las Vegas, NV

Research site
(Unclaimed)
Location
3920 S Eastern Avenue, Suite 202, Las Vegas, Nevada, United States of America

Site insights

Top conditions

Top treatments

Paclitaxel
Carboplatin
Docetaxel
Nivolumab
Cisplatin
Bevacizumab
Atezolizumab
Pembrolizumab
Ipilimumab
Gemcitabine

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

86 of 448 total trials

9-ING-41 in Patients With Advanced Cancers

GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and e...

Active, not recruiting
Neoplasm of Lung
Neoplasms Pancreatic
Drug: Gemcitabine - 21 day cycle
Drug: Lomustine

Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation...

Enrolling
Waldenström Macroglobulinemia
Marginal Zone Lymphoma
Drug: BGB-16673

The purpose of this neoadjuvant study is to compare nivolumab plus chemotherapy and chemotherapy alone in terms of safety and effectiveness, and to d...

Active, not recruiting
Non Small Cell Lung Cancer
Drug: Pemetrexed
Drug: Cisplatin

The primary objective of this study is:• To evaluate the long-term safety of fostamatinib in subjects with warm antibody autoimmune hemolytic anemia...

Invitation-only
Warm Antibody Autoimmune Hemolytic Anemia
Drug: Fostamatinib disodium

To compare efficacy between zanubrutinib versus bendamustine and rituximab in patients with previously untreated CLL/SLL, as measured by progression...

Active, not recruiting
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Rituximab
Drug: Venetoclax

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with end...

Enrolling
Early Breast Cancer
Drug: Endocrine Therapy of Physician's Choice
Drug: Abemaciclib

This is a Phase 2 open-label, multicenter study evaluating tolerability and efficacy of navitoclax alone or when added to ruxolitinib in participants...

Active, not recruiting
Myelofibrosis (MF)
Drug: Navitoclax
Drug: Ruxolitinib

This is a Phase 1b/2 study to investigate the efficacy and safety of LBL-007 plus Tislelizumab when administered in combination with bevacizumab plus...

Enrolling
Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
Drug: 5-Fluorouracil
Drug: Tislelizumab

The primary objective of the Phase 2 portion of the study is to characterize the clinical activity of maintenance therapy with GRT-C901/GRT-R902 (pat...

Active, not recruiting
Colorectal Neoplasms
Drug: Ipilimumab
Drug: Atezolizumab

This study is being done to see how safe and effective abemaciclib is when given together with abiraterone acetate plus prednisone in participants wi...

Active, not recruiting
Prostate Cancer
Drug: Prednisone
Drug: Placebo

The primary purpose of this study is to compare pembrolizumab/vibostolimab to pembrolizumab with respect to recurrence-free survival (RFS). The prima...

Active, not recruiting
Melanoma
Biological: Pembrolizumab/Vibostolimab
Biological: Pembrolizumab

The purpose of this study is to evaluate the efficacy and safety of atezolizumab in combination with tiragolumab compared with durvalumab in particip...

Active, not recruiting
Non-small Cell Lung Cancer (NSCLC)
Drug: Tiragolumab
Drug: Durvalumab

This study will evaluate the efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and...

Active, not recruiting
Small Cell Lung Cancer
Drug: Carboplatin
Drug: Tiragolumab

This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of avelumab in combination with axitinib and of sunitinib monotherap...

Active, not recruiting
Renal Cell Cancer
Drug: Axitinib (AG-013736)
Drug: Avelumab (MSB0010718C)

This study will assess the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Lo...

Active, not recruiting
Low Grade Ovarian Serous Adenocarcinoma
Ovarian Cancer
Drug: avutometinib (VS-6766) and defactinib
Drug: avutometinib (VS-6766)

The purpose of this study is to investigate experimental medication BMS-986253 in combination with Nivolumab or Nivolumab plus Ipilimumab in particip...

Active, not recruiting
Melanoma
Cancer
Biological: Ipilimumab
Other: Placebo

This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It...

Enrolling
Urothelial Carcinoma
Drug: pembrolizumab
Drug: disitamab vedotin

This is a global, randomized, double-blind, placebo-controlled, multicenter phase 3 clinical trial to compare the efficacy and safety of fruquintinib...

Active, not recruiting
Metastatic Colorectal Cancer
Metastatic Colon Cancer
Drug: Fruquintinib
Drug: Placebo

The primary objective of this study is to evaluate the safety and tolerability of H3B-6545 and palbociclib when administered in combination in order...

Active, not recruiting
Genes, Erbb-2
Receptors, Estrogen
Drug: H3B-6545 (150, 300, 450 mg)
Drug: Palbociclib (75, 100, 125 milligram [mg])

This is a Phase 1/2 study of HST-1011, a CBL-B inhibitor, being developed for the treatment of patients with advanced solid tumors, who relapsed whil...

Enrolling
Relapsed Cancer
Solid Tumor, Adult
Drug: HST-1011
Biological: Cemiplimab

Trial sponsors

National Cancer Institute (NCI) logo
S
Alliance for Clinical Trials in Oncology logo
Pfizer logo
Seagen logo
ECOG-ACRIN Cancer Research Group logo
Bristol-Myers Squibb (BMS) logo
Roche logo
N
BeiGene logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems